Want to see CBUS full AI Analyst Report?
Top Page
Cibus
(NASDAQ:CBUS)
Select Model
Select Model
Rating:46Neutral
Price Target:
$1.50
▼(-10.71% Downside)
Action:Reiterated
Date:08/18/26
The score is driven primarily by weak financial performance (deep losses, ongoing cash burn, thin equity despite improved debt levels). Technicals are mixed/neutral and do not provide strong confirmation of upside momentum. Valuation metrics offer little support due to negative earnings and no dividend yield. The earnings call adds some credit for cost discipline, regulatory progress, and early commercialization steps, but near-term liquidity/runway and execution dependencies keep overall risk elevated.
Positive Factors
Regulatory progress supports commercialization
Favorable regulatory determinations across several jurisdictions reduce barriers for Cibus’s gene-edited traits and support future launch plans. The progress strengthens the platform’s commercial credibility, although market benefits will still depend on implementation and partner execution.
Negative Factors
Short cash runway and elevated future funding risk
A runway extending only into early 2027 leaves limited time for Cibus to reach meaningful commercialization before potentially needing additional capital. The higher cash-usage target increases funding pressure and could constrain investment or require financing on unfavorable terms.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory progress supports commercialization
Favorable regulatory determinations across several jurisdictions reduce barriers for Cibus’s gene-edited traits and support future launch plans. The progress strengthens the platform’s commercial credibility, although market benefits will still depend on implementation and partner execution.
Read all positive factors
Cibus (CBUS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$105.47M
Dividend YieldN/A
Average Volume (3M)112.00K
Price to Earnings (P/E)―
Beta (1Y)2.52
Revenue Growth-10.30%
EPS Growth84.17%
CountryUS
Employees118
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.65
Shares Outstanding76,428,960
10 Day Avg. Volume56,403
30 Day Avg. Volume112,005
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.65
Price to Sales (P/S)21.88
P/FCF Ratio-1.56
Enterprise Value/Market Cap3.52
Enterprise Value/Revenue85.34
Enterprise Value/Gross Profit186.61
Enterprise Value/Ebitda-6.45
Forecast
1Y Price Target
$25.00Price Target Upside1388.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.85
Revenue Forecast (FY)$5.20M
Cibus Business Overview & Revenue Model
Company Description
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertiliz...
How the Company Makes Money
Cibus’s revenue model is based on monetizing its crop-trait development platform by commercializing traits in seeds through third parties rather than operating as a traditional seed producer. The company primarily aims to generate revenue via lice...
Cibus Earnings Call Summary
Earnings Call Date:Aug 13, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 05, 2026
Earnings Call Sentiment Neutral
The call presented a balanced mix of progress and remaining challenges. Positive developments include cost reductions, regulatory validations across multiple jurisdictions, initial commercial revenue from sustainable ingredients, tangible rice partnership expansions (Interoc and others), and an articulated path to larger royalty streams with a peak addressable rice royalty opportunity of over $200M. Counterbalancing these positives are a small current revenue base, a short cash runway (into early Q1 2027) with an increased net cash usage target (~$35M), sizable quarterly net losses, and multi-step, partner-dependent commercialization milestones that will stretch realization of royalties over multiple years. Given the combination of meaningful technical/regulatory progress and near-term financial constraints and execution risks, the overall tone is cautiously constructive but pragmatic.Positive Updates
Improved Cash Position and Reduced Cash Usage
Cash and cash equivalents of $20.4M as of June 30, 2026. Quarterly cash usage declined ~19% sequentially and ~31% year-over-year. Management targets a net cash usage run rate exiting 2026 of approximately $35M and expects existing cash to fund operations into early Q1 2027.
Negative Updates
Limited Absolute Revenue Today
Quarterly revenue remains small at $1.0M and is still dependent on partner milestones and scale-up; current commercial revenues are nascent despite encouraging growth trajectories.
Read all updates
Q2-2026 Updates
Positive
Negative
Improved Cash Position and Reduced Cash Usage
Cash and cash equivalents of $20.4M as of June 30, 2026. Quarterly cash usage declined ~19% sequentially and ~31% year-over-year. Management targets a net cash usage run rate exiting 2026 of approximately $35M and expects existing cash to fund operations into early Q1 2027.
Read all positive updates
Company Guidance
Management provided specific financial and commercial guidance: cash and cash equivalents were $20.4M as of June 30, 2026, quarterly cash usage has declined ~19% sequentially and ~31% year‑over‑year, and the company is targeting ~ $9M cash usage for the quarter and an exit net cash‑usage run rate of ~ $35M (sufficient to fund operations into early Q1 2027). Revenue was $1.0M in Q2 (vs. $0.9M prior year) and $2.7M YTD (up 35% YoY); R&D expense was $8.5M and SG&A $5.4M (combined R&D+SG&A down nearly $5M YoY); non‑cash royalty interest expense was $9.5M this quarter; net loss was $22.1M (EPS $0.29) versus $26.6M (EPS $0.61) a year ago. Operational and commercial milestones include additional scale‑up orders for biofragrances expected in H2 2026 (a biofragrance partnership could be $20–40M of annual revenue when fully commercialized), rice royalties anticipated to start in 2028 and build in 2029 with a peak royalty opportunity of >$200M annually across ~5–7M acres, a U.S. launch planned in 2029 with Albaugh, and a company goal of a 12‑month turnaround for edits across crops.Cibus Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
28
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.35M | 3.64M | 4.26M | 1.82M | 157.00K | 25.99M |
| Gross Profit | 1.99M | -2.28M | -2.60M | 1.42M | -1.38M | -2.57M |
| EBITDA | -57.53M | -90.77M | -241.63M | -314.58M | -15.21M | -25.43M |
| Net Income | -98.19M | -127.08M | -251.39M | -267.63M | -16.89M | -29.20M |
Balance Sheet | ||||||
| Total Assets | 313.45M | 305.05M | 350.07M | 544.41M | 22.42M | 37.19M |
| Cash, Cash Equivalents and Short-Term Investments | 20.43M | 9.92M | 14.43M | 32.70M | 3.43M | 13.82M |
| Total Debt | 32.74M | 267.96M | 36.29M | 24.62M | 13.91M | 17.88M |
| Total Liabilities | 298.64M | 283.22M | 252.24M | 206.12M | 15.19M | 23.06M |
| Stockholders Equity | 14.80M | 21.83M | 92.16M | 293.47M | 7.23M | 14.13M |
Cash Flow | ||||||
| Free Cash Flow | -46.32M | -51.17M | -58.85M | -50.53M | -20.88M | -19.31M |
| Operating Cash Flow | -46.05M | -50.59M | -58.04M | -46.21M | -19.36M | -18.81M |
| Investing Cash Flow | -224.00K | -578.00K | -808.00K | 55.06M | -1.52M | 11.20M |
| Financing Cash Flow | 30.25M | 46.65M | 40.60M | 20.32M | 9.99M | 3.74M |
Cibus Technical Analysis
Negative
1.68
Price Trends
1.55
Negative
1.60
Negative
1.85
Negative
Market Momentum
-0.05
Negative
44.10
Neutral
64.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CBUS, the sentiment is Negative. The current price of 1.68 is above the 20-day moving average (MA) of 1.47, above the 50-day MA of 1.55, and below the 200-day MA of 1.85, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 44.10 is Neutral, neither overbought nor oversold. The STOCH value of 64.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CBUS.
Cibus Risk Analysis
Cibus disclosed 44 risk factors in its most recent earnings report. Cibus reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cibus Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $105.47M | -0.84 | -320.60% | ― | -10.30% | 84.17% | |
46 Neutral | $33.56M | -0.69 | -156.02% | ― | -95.74% | -23.18% | |
46 Neutral | $78.19M | -6.23 | -200.67% | ― | ― | -39.90% | |
44 Neutral | $322.23M | -2.71 | -63.05% | ― | -51.65% | 91.93% | |
42 Neutral | $28.03M | -3.56 | -71.47% | ― | -100.00% | -55.90% |
* Healthcare Sector Average
CBUS
Cibus
1.41
-0.18
-11.32%
CRVO
CervoMed
2.21
-4.67
-67.88%
XFOR
X4 Pharmaceuticals
3.35
-0.39
-10.43%
ABVC
ABVC BioPharma
1.09
-1.68
-60.65%
OKYO
OKYO Pharma Limited Sponsored ADR
1.49
-1.23
-45.22%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.